Nanogen Pharmaceutical Biotechnology JSC has signed an agreement with India's Vekaria Healthcare LLP for tech transfer, production, and distribution of Nanocovax vaccines.
|Vekaria Healthcare LLP will produce Nanocovax vaccine by Nanogen in India |
The agreement will be the basis for the two companies to enter into a deeper discussion on the details of the cooperation related to the large-scale production and distribution of Nanocovax vaccine when it receives the license for emergency use.
Nanocovax is Vietnam's domestically developed coronavirus vaccine candidate. The vaccine has begun Phase 3 clinical trials with positive results.
Nanogen is coordinating with domestic agencies to promote the testing process to soon get approval for emergency use.
Previously, Nanogen authorised Vietnamese Ambassador to India Pham Sanh Chau as its representative to negotiate with the Indian partner on technology transfer and clinical trials of the Nanocovax vaccine.
The ambassador said that the tie-up between Nanogen and Vekaria Healthcare LLP is of great significance as the pandemic is raging in India, Vietnam, and many parts of the world. The early rollout of Nanocovax for testing, production, and distribution on a large scale will contribute to the fight against the pandemic.
Vekaria Healthcare LLP, a subsidiary of Vekaria Group, has researched and studied many potential COVID-19 vaccines before choosing Nanocovax for production.